We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > DMARD

News List

Rinvoq® shows positive results in rheumatoid arthritis post-hoc analysis EuropeanPharmaceuticalReview
November 10, 2021
AbbVie has announced new results from a post-hoc analysis of the Phase III SELECT-BEYOND clinical trial evaluating Rinvoq® (upadacitinib; 15mg, once daily) in patients with moderate...
Novartis, Cadila Healthcare lead digital marketing space for ankylosing spondylitis in India: GlobalData expresspharma
May 21, 2021
Novartis and Cadila Healthcare are the only companies to offer support to AS patients through digital channels, finds GlobalData.
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis pharmatimes
January 22, 2021
The National Institute for Health and Care Excellence (NICE) has published its final appraisal determination (FAD) recommending the use of Gilead Sciences and Galapagos’ Jyseleca (filgotinib) for the treatment of rheumatoid arthritis (RA).
Janssen's Tremfya approved for active psoriatic arthritis pharmatimes
November 27, 2020
The European Commission has approved Janssen’s Tremfya (guselkumab) as a first-in-class treatment for active psoriatic arthritis (PsA).